Investor Presentation on Financial results for quarter and year ended on March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prevest Denpro reported FY25 total revenue of ₹67.09 Cr, up 13.16% YoY, driven by balanced domestic and export growth. EBITDA rose 15.17% to ₹26.15 Cr with margin expanding to 38.98% (from 38.30%), and PAT grew 12.51% to ₹18.16 Cr at a 27.06% margin. The company sits on ₹60.90 Cr in cash reserves and remains completely debt-free. Q4FY25 revenue came in at ₹18.45 Cr (+11.69% YoY) with EBITDA margin of 39.03%. Exports span 100+ countries, with Asia contributing 49% of revenue, Europe 27%, Africa 18%, and the Americas 5%. Management outlined a 'Vision 2026' roadmap focused on Digital Dentistry R&D, new product pipeline, global expansion, and M&A opportunities in complementary dental segments. Valuation is quoted at P/E of 31.91 versus an industry average of 54.92.
Strong fundamentals — debt-free status, healthy cash pile of ₹60.90 Cr, and double-digit growth across revenue, EBITDA, and PAT — should be supportive for the stock. The Vision 2026 plan signals management's confidence in scaling through new products, geographic expansion, and potential acquisitions, which could be a positive catalyst if execution holds.